Drug Trial Radar · NCT04984837
Study of Lacutamab in Peripheral T-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Actual
Start
Oct 5, 2021
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- The Lymphoma Academic Research OrganisationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Innate Pharma
- First posted
- Aug 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype), Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma (ATL), Hepatosplenic T-cell lymphoma (HSTL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL). The design is non comparative meaning that non comparison between arms will be performed as the control arm will ensure that the assumptions used for sample size calculation are verified. For that reason, randomization is unbalanced in favor of the experimental arm (2:1).
Conditions
- Peripheral T Cell Lymphoma
- Relapse/Recurrence
Interventions
LacutamabDrug
750 mg/IV
GemcitabineDrug
1000 mg/m²
OxaliplatineDrug
100 mg/m²
Primary outcomes
What the sponsor says the trial is designed to measure.
- median modified progression-free survival (mPFS) - CT-basedTime frame: 5,5 years.
Locations
64 sites in 4 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Anderlecht, Belgium
VZW ZAS
Antwerp, Belgium
A. Z. Sint-Jan
Bruges, Belgium
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Brussels, Belgium
Cliniques universitaires Saint-Luc - Université catholique de Louvain
Brussels, Belgium
Grand Hôpital de Charleroi
Charleroi, Belgium
UZ Antwerpen
Edegem, Belgium
HELORA - Hôpital de La LouvièreSite Jolimont
Haine-Saint-Paul, Belgium
CHU de LIEGE - Domaine Sart Tilman
Liège, Belgium
Clinique CHC MontLégia
Liège, Belgium
CHR Verviers
Verviers, Belgium
CHU Dinant Godinne - UCL Namur - YVOIR
Yvoir, Belgium
CHU d'Amiens
Amiens, France
CHU d'Angers
Angers, France
CH d Avignon - Hopital Henri Duffaut
Avignon, France
CH de la Côte Basque - Hôpital de Bayonne
Bayonne, France
Institut Bergonié
Bordeaux, France
CHU de Caen - Côte de Nacre - IHBN
Caen, France
CH Métropole Savoie
Chambéry, France
CHU de Clermont Ferrand - Estaing
Clermont-Ferrand, France
APHP - Hôpital Henri Mondor
Créteil, France
CHU de Dijon BOURGOGNE - Hôpital François Mitterand
Dijon, France
CH de Dunkerque
Dunkirk, France
CHD de Vendée
La Roche-sur-Yon, France
CHU de Grenoble - Hôpital Albert Michallon
La Tronche, France
Ch de Versailles - Hopital Andre Mignot
Le Chesnay, France
CH du Mans
Le Mans, France
CHRU de Lille - Hôpital Claude Hurriez
Lille, France
Hôpital Saint Vincent-De-Paul
Lille, France
Chu de Limoges - Hopital Dupuytren
Limoges, France
Centre Leon Berard
Lyon, France
Chu de Meaux
Meaux, France
CHU de Montpellier
Montpellier, France
CH de Mulhouse
Mulhouse, France
CHU de Nancy - Brabois
Nancy, France
CHU de Nantes - Hôtel Dieu
Nantes, France
CHU de Nîmes
Nîmes, France
CHR d'Orléans
Orléans, France
APHP - Hopital Necker
Paris, France
APHP - Hôpital de la Pitié Salpétrière
Paris, France
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.